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Genome-wide association studies (GWAS) have identified hundreds of genetic variants that are associated with lipid phenotypes.
However, data supporting a functional role for these variants in the context of lipid metabolism are scarce. We investigated the associ-
ation of the lipoprotein lipase (LPL) variant rs13702 with plasma lipids and explored its potential for functionality. The rs13702 minor
allele had been predicted to disrupt a microRNA (miR) recognition element (MRE) seed site (MRESS) for the humanmicroRNA-410 (miR-
410). Furthermore, rs13702 is in linkage disequilibrium (LD) with several SNPs identified by GWAS.We performed ameta-analysis across
ten cohorts of participants that showed a statistically significant association of rs13702 with triacylglycerols (TAG) (p ¼ 3.18 3 1042)
and high-density lipoprotein cholesterol (HDL-C) (p ¼ 1.35 3 1032) with each copy of the minor allele associated with 0.060 mmol/l
lower TAG and 0.041 mmol/l higher HDL-C. Our data showed that an LPL 30 UTR luciferase reporter carrying the rs13702 major T allele
was reduced by 40% in response to amiR-410mimic.We also evaluated the interaction between intake of dietary fatty acids and rs13702.
Meta-analysis demonstrated a significant interaction between rs13702 and dietary polyunsaturated fatty acid (PUFA) with respect to TAG
concentrations (p ¼ 0.00153), with the magnitude of the inverse association between dietary PUFA intake and TAG concentration
showing 0.007 mmol/l greater reduction. Our results suggest that rs13702 induces the allele-specific regulation of LPL by miR-410
in humans. This work provides biological and potential clinical relevance for previously reported GWAS variants associated with plasma
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Introduction
The lipoprotein lipase (LPL) (MIM 609708) locus encodes
a crucial enzyme in lipoprotein metabolism where its
activity partially determines concentrations of circulating
triacylglycerols (TAG) and high-density lipoprotein choles-
terol (HDL-C). Furthermore, abnormalities in LPL expres-
sion and protein activity have been implicated in the
pathogenesis of cardiovascular disease (CVD).1,2 Although
environmental factors can modulate an individual’s sus-
ceptibility to CVD, twin studies have demonstrated that
genetic factors also play a significant role.3 Indeed, rare
mutations within the LPL locus are frequent in hypertrigly-
ceridemic individuals and candidate gene studies of
LPL have identified several common and functional
missense single-nucleotide polymorphisms (SNPs) that
associate with variability in lipid concentrations.1,4,5 Addi-
tional studies reported statistically significant interactions
between common LPL SNPs and dietary fats, suggesting
that dietary habits may influence the extent to which
LPL affects lipid phenotypes, or vice versa.6–8
Recent genome-wide association studies (GWAS) have
identifiedhundreds of SNPs influencingphysiological traits
associatedwithCVD, including several newvariantswithin
LPL.9–12However, for themajority of these SNPs, functional
mechanisms through which the SNP may be modulating
risk are unknown.13,14 It may be that these SNPs are proxies
for a functional variant or are explained by a yet-unknown
mechanism. Until the underlying biology explaining the
mechanisms for the effect of these SNPs on lipid metabo-
lism are revealed, the use of this information in CVD
prevention and therapeutics will remain limited.15
SNPs causing exonic missense mutations or located
within noncoding control regions have been recognized
as promising candidates for association and functional
studies.3,16 MicroRNAs (miR) are small 20–24 nucleotide
noncoding RNAs that act as posttranscriptional inhibitors
of gene expression by binding tomiR recognition elements
(MRE) within the 30 UTR of their target mRNAs.17 Themost
critical region for binding and repression of mRNA by a
miR are positions 2–7 of the MRE, referred to as the seed
site. Single-point mutations in MRE seed sites (MRESS)
have been shown to reduce or abolish miR-mediated
repression in vitro.8,18 Furthermore, several supporting
examples have been reported in population-based studies
in which a SNP falling within aMRE or MRESS is associated
with phenotypic variation.19–21
Recently, a genome-wide bioinformatic analysis uncov-
ered 87 SNPs previously reported in GWAS, or SNPs in
strong linkage disequilibrium (LD) with GWAS variants,
that alter predicted mRNA-miR interactions.22 One of the
SNPs identified, rs13702, maps to the LPL 30 UTR and
is in LD with three SNPs (rs326, rs2083637, and
rs10105606) identified in GWAS as significant modulators
of lipid traits.23–25 The minor allele of rs13702 itself has
been associated with both lower TAG and greater HDL-C
concentrations in cross-sectional studies and with longitu-6 The American Journal of Human Genetics 92, 5–14, January 10, 201dinal changes over time.9–11 Interestingly, individuals
carrying the rs13702 minor allele have been found to
have elevated postheparin LPL activity.12 The bio-
informatic analysis suggests a functional role for rs13702
through disruption of a predicted MRESS for miR-410 in
the LPL 30 UTR (Figure S1 available online). A role for
human miR-410 has been demonstrated in glucose-stimu-
lated insulin secretion (GSIS) in vitro.26 There is also
evidence for expression of miR-410 in tissues where LPL
is most active.27,28 Currently there are no data directly
linking miR-410 to LPL or to lipid metabolism in general.
The analysis identifying rs13702 as a functional candi-
date was focused on SNPs related to the binding of miRs,
but SNPs outside of the LPL 30 UTR and in LD with
rs13702, rs326, rs2083637, or rs10105606 were not
analyzed for functional potential. Here, we investigated
the LD structure of the LPL locus and confirm rs13702 as
having the most robust functional hypothesis of all the
SNPs in LD with those reported in GWAS. Furthermore,
we investigate the hypothesis that the gain-of-function
(e.g., improved lipid profiles) associations previously
observed for rs13702, and for GWAS SNPs in LD with
rs13702 are the result of an allele-specific interaction of
the LPLmRNA with miR-410. To replicate previous associ-
ations of rs13702 with lipid traits, we performed a meta-
analysis with genotype and phenotype data from 27,756
individuals from the Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE) Consortium Nutri-
tion working group.29,30 To test the functionality of
rs13702, we analyzed expression of miR-410 in a panel of
human tissues and performed an in vitro allele-specific
luciferase reporter assay. The LPL promoter contains a func-
tional peroxisome proliferator response element (PPRE),
and PPREs are responsive to fatty acids.31,32 Therefore, we
hypothesized that the proposed allele-specific regulatory
effect of rs13702 may differentially regulate LPL levels in
response to dietary fat. To examine this hypothesis, we
meta-analyzed our cohort data for statistically significant
interactions between rs13702 and dietary fatty acids in
modulation of lipid phenotypes.
Our results indicate that miR-410 is a regulator of LPL in
humans. Furthermore, we demonstrate that the LPL 30 UTR
SNP rs13702 induces an allele-specific interaction with
miR-410, functional data that may explain the observed
associations. Our meta-analysis of interaction data sug-
gests that this effect may be further modulated by dietary
PUFA. Building on previous bioinformatic analyses, we
provide biological and potential clinical relevance for a
common variant at the LPL locus.Material and Methods
Ethics Statement
All participants from contributing cohorts gave written informed
consent to participate in genetic analysis. All cohort studies have
approval from local IRB and/or oversight committees.3
Study Samples
The data used in this study were obtained from ten cohorts partici-
pating in the CHARGE consortium. These populations are the
Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovas-
cular Health Study (CHS), The FraminghamHeart Study (Framing-
ham), the Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) Study, the Health, Aging and Body Composition (Health
ABC) Study, the Helsinki Birth Cohort Study (HBCS), the Invec-
chiare in Chianti (InCHIANTI) Study, the Multi-Ethnic Study of
Atherosclerosis (MESA), the Rotterdam Study (Rotterdam), and
the Young Finns Study (YFS).
Genotyping and Imputation
Genotyping was performed in each cohort separately with Affy-
metrix 6.0 high-density SNP marker (GOLDN). The Illumina
Human1M-Duo BeadChip system was used for genotyping in
Health ABC; Illumina 670K platforms in YFS; and the 250K Nsp,
250K Sty, and a 50K gene centric Affymetrix platforms in
FHS. Genotypes were imputed separately in each cohort with
MACH (ARIC, HBCS, InCHIANTI, and YFS), IMPUTE2 (MESA),
and Bimbam (CHS).
Determination of LD Structure of the LPL Locus
The 1000 Genomes data was queried with the 1000 Genomes
project webtool. The coordinates spanning the region 40 kb
up- and downstream of the LPL locus were inputted, chr8:
19,756,582–19,865,770. The resulting .ped and .info files were
loaded into Haploview and LD calculated with the pairwise LD
calculation tool with the settings of r2 > .7 and MAFR 0.10.
Statistical Analysis
Each cohort performed association analyses separately for main
effect and interaction analyses. All studies utilized a linear regres-
sion analysis (or linear mixed effects model in family studies to
account for familial correlations) implementing an additive
genetic model while adjusting for age, gender, BMI, field center,
and population substructure variables. Interaction analyses
included an interaction term of the dietary variable (as a contin-
uous variable) 3 SNP being analyzed. Furthermore, participants
with prior CVD events and/or on lipid-lowering medications
and nonwhite participants from each cohort were excluded from
analysis. TAG values were log transformed in each cohort before
analysis.
For meta-analysis of main and interaction effects, we performed
an inverse variance-weighted analysis combining regression esti-
mates and their standard errors with the METAL software
package.33 A Bonferroni multiple testing cutoff was utilized for
interaction analysis; 3 traits 3 2 SNP 3 3 dietary factors ¼ 18.
0.05/18 ¼ 0.0027. All plots were generated with R statistical
software.
Expression Profile of miR-410 in Selected Human
Tissues
A total of 1 mg of RNA from different human tissues from First-
Choice Total RNA (Ambion) were reverse transcribed with the
miScript II RT Kit (QIAGEN) and miRNA quantified with miScript
SYBR Green PCR kit (QIAGEN) with primers specific for human
miR-410 (miScript Primer Assay, QIAGEN). Values were normal-
ized to the housekeeping gene SNORD 61. All experiments were
performed in duplicate. miR-410 expression in the different tissues
was relative to lung miR-410 expression.The30 UTR Luciferase Reporter Assays
The Expand High Fidelity PCR kit (Roche) was used to amplify the
LPL 30 UTR sequence with genomic DNA from subjects homozy-
gous for either rs13702 allele. Primers were designed to amplify
535 nucleotides of the LPL genomic sequence. Included in the
primers were the restriction enzyme sites XhoI for the forward
primer (aactcgagGATGTATTGGAACATGTCGGAGTA) and NotI
for the reverse (agcggccgcGTGGTAATAAAATGTTGTCAATTT
TATTAAAAGC).
The polymerase chain reaction products were directionally
cloned downstream of the Renilla luciferase open reading frame
in the psiCHECK2TM vector (Promega) that also contains a
constitutively expressed firefly luciferase gene, which is used to
normalize transfections.
All constructs were confirmed by sequencing. COS-7 cells were
plated into 12-well plates (Costar) and cotransfected with 1 mg
of the indicated 30 UTR luciferase reporter vectors and with
20 nmol/l of the miR-410 mimic or negative control mimic
(Cn-miR) (Dharmacon) via Lipofectamine 2000 (Invitrogen).
Luciferase activity was measured with the Dual-Glo Luciferase
Assay System (Promega). Renilla luciferase activity was normalize
to the corresponding firefly luciferase activity and plotted as
a percentage of the control (Cn-miR). Experiments were per-
formed in triplicate, and at least three independent experiments
were performed.Results
The LD Structure of the LPL Locus Reveals rs13702 as
the Most Likely Functional Candidate Explaining
GWAS Results
rs13702 falls within a high confidence prediction for
a miR-410 MRESS in the LPL 30 UTR. Furthermore, there
is evidence for coexpression between LPL and miR-410.22
These data suggest a hypothesis for rs13702 as the causal
variant explaining the associations of rs326, rs2083637,
and rs10105606 observed in GWAS. To determine whether
rs13702 is the most likely functional candidate to explain
the observed GWAS associations, we investigated the LD
structure of all SNPs spanning a region 40 kbp upstream
and downstream of the LPL locus with a minor allele
frequency (MAF) R0.10 by using 1000 Genomes data
analyzed in Haploview.34,35 This analysis identified 27
tagging SNPs capturing 241 SNPs across the region. The
LD block containing rs13702 consisted of 68 SNPs ranging
from intron 6 to the intergenic region downstream of LPL
(Table S1).
To investigate the functional potential of the 67 SNPs in
LD with rs13702, we utilized the SNPinfo web portal,
which predicts the effect of a SNP on protein structure,
gene regulation, and splicing.36 Only 2 of the 68 SNPs
within the rs13702 LD block, rs13702 and rs15285, had
functional predictions (Table S2). Both rs13702 and
rs15285 disrupt MRESS predictions from the microrna.
org database.37 The top-ranking prediction that rs15285
disrupts is an MRESS in the LPL 30 UTR for miR-571. The
top-ranking prediction that rs13702 disrupts is an MRESS
for miR-410 (Table S3 and Figure S1). The LPL-miR-571American Journal of Human Genetics 92, 5–14, January 10, 2013 7
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Table 2. Main Effect Associations of LPL SNPs
SNP Trait Beta SE p
rs13702 TAG 0.060 0.004 9.56 3 1043
TAGa 0.060 0.007 3.18 3 1042
HDL-C 0.041 0.003 1.79 3 1033
HDL-Ca 0.040 0.003 1.35 3 1032
LDL-C 0.002 0.010 0.847
LDL-Ca 0.005 0.008 0.551
rs2083637 TAG 0.063 0.005 1.42 3 1043
HDL-C 0.043 0.004 1.50 3 1034
LDL-C 0.006 0.010 0.529
Results of meta-analysis across ten cohorts for two LPL SNPs. Each cohort per-
formed association analyses separately for main effects. All studies utilized
a linear regression analysis implementing an additive genetic model while
adjusting for age, gender, BMI, field center, and population substructure vari-
ables. Meta-analysis of main effects was performed with an inverse variance
weighted analysis.
aMeta-analysis performed with GOLDN data.8 The American Journal of Human Genetics 92, 5–14, January 10, 201prediction is in the top 15th percentile, and the LPL-miR-
410 prediction is in the top 5th percentile of mirSVR scores
from microrna.org, which is considered an empirical
probability of downregulation.37 Furthermore, only the
predicted LPL-miR-410 interaction has supporting coex-
pression evidence.22 Based on these data we determined
the predicted LPL-miR-410 interaction disrupted by
rs13702 as the best functional candidate to explain the
associations observed in GWAS.
Meta-analysis of Association between LPL Variants
and Lipid Phenotypes in 27,756 Subjects Replicates
Previous Association Data
We next investigated whether previously reported associa-
tions of rs13702 and rs2083637 with HDL-C and TAG
levels could be replicated in 27,756 subjects participating
in the CHARGE Consortium Nutrition working group. In
addition to HDL-C and TAG, we also investigated the asso-
ciation of these SNPs with another predictor of CVD risk,
low-density lipoprotein cholesterol (LDL-C) concentra-
tions. We included the intergenic rs2083637 in our anal-
ysis because itmay be acting as a geneticmarker for a causal
rs13702 variant. The remaining variants from GWAS in LD
with rs13702 (rs326 and rs10105606) were not available in
the majority of participating cohorts and therefore were
not analyzed. Table 1 summarizes the demographic and
genotypic characteristics of the ten participating cohorts.
The rs13702 SNP showed significant association with
TAG (p ¼ 3.182 3 1042) and HDL-C (p ¼ 1.316 3 1032),
with each copy of the minor allele showing 0.060 mmol/l
lower TAG and 0.041 mmol/l higher HDL-C. The
rs2083637 showed similar associations with TAG (p ¼
1.42 3 1043) and HDL-C (p ¼ 1.50 3 1034) having
the same direction of effect and similar magnitude as
rs13702. No association was observed for either SNP with
LDL-C (Table 2). The only SNP available in the GOLDN3
Figure 1. Population-Specific Effect of
the rs13702 SNP on TAG and HDL-C
Population-specific associations between
rs13702 and (A) TAG and (B) HDL-C.
Plotted are the population-specific regres-
sion coeffecients (Beta) and SEs repre-
senting change in TAG (mmol/l) and
HDL-C (mmol/l) per copy of the
rs13702 minor C allele. Data are adjusted
for covariates age, sex, BMI, field center,
and population substructure variables.
The overall associations from meta-anal-
ysis are also plotted.population was rs13702, so for comparison we show the
meta-analysis results in which the GOLDN population
data are excluded. The effect of rs13702 on both TAG and
HDL-C was consistent across the ten participating cohorts
(Figures 1A and 1B).The rs13702 Minor C Allele Abolishes the Response of
a Functional miR-410 MRE in the hLPL 30 UTR
The rs13702minor allele was previously shown to abrogate
a high confidence prediction for a miR-410 seed site in the
LPL 30 UTR (Figure S1). To determine the validity of this
functional prediction, we first confirmed the expression of
miR-410 in tissues where LPL is most active.2 To do so, we
assessed miR-410 expression levels in a panel of human
tissues (Figure 2A).Ourdata showthatmiR-410 iswidely ex-
pressed in human tissues with expression highest in testis.
We next assessed the functionality of the predicted miR-
410 binding site within the LPL 30 UTR. A 535 nucleotide
segment of the LPL 30 UTR containing the rs13702 position
was cloned into the psiCHECK2TM luciferase reporter via
genomic DNA of subjects homozygous for either rs13702
allele. COS-7 cells were cotransfected with either a miR-
410 mimic or a control mimic with either the T or C allele
LPL luciferase reporter construct. The major T allele con-
struct, when cotransfected with a miR-410 mimic, showed
a 40% decrease in luciferase activity compared to control
mimic. This effect was abolished when the same experi-
ment was conducted with the minor C allele reporter
construct (Figure 2B). Furthermore, the T allele construct
responded in a dose-dependent fashion in response to
increasing concentrations of miR-410 (Figure 2C). These
data suggest that human LPL transcripts harboring the
rs13702 major T allele are targeted and their translation
partially inhibited by miR-410 and that this interaction is
abrogated in transcripts containing the minor C allele.Interaction Analysis Suggests Dietary PUFA Further
Modulates the Effect of rs13702 on Lipid
Concentrations
To determine the extent to which modulation of lipid
levels by rs13702 is modified by dietary fatty acid intake,Thewe performed a gene-by-diet interaction meta-analysis.
We investigated the interaction of two SNPs (rs13702
and rs2083637) with three dietary variables (saturated fat
[SFA], monounsaturated fat [MUFA], and polyunsaturated
fat [PUFA]) on three outcome variables (TAG, HDL-C, and
LDL-C). Mean PUFA ranged from 3.38% to 8.72% of total
energy across participating cohorts (Table 1). One value
survived Bonferroni adjustment (p < 0.0027), where
rs13702 showed a significant interaction with dietary
PUFA modulating TAG as a continuous variable (p ¼
0.00153) with the magnitude of the inverse association
between dietary PUFA intake and TAG concentration
showing 0.007 mmol/l greater reduction per minor allele
(Table 3). As with our main effect analyses, the only SNP
available in the GOLDN population was rs13702, so for
comparison with other SNPs we report the interaction
meta-analysis results (p ¼ 0.00133) for the effect of
rs13702 3 PUFA interaction on TAG in which the GOLDN
population data are excluded. Results were similar in
magnitude but opposite in direction for HDL-C, although
the interaction was not statistically significant after correc-
tion for multiple testing (p ¼ 0.045). These data sug-
gest that for each copy of the minor rs13702 allele, the
subject will have lower TAG in association with greater
intake of PUFA. A forest plot depicts the population-
specific effects of the rs13702 minor allele’s interaction
with PUFA on TAG and HDL-C (Figures 3A and 3B). No
other significant interactions between dietary fat and LPL
SNPs were observed.Discussion
We identify rs13702 as the strongest functional candidate
within a large LDblock of the LPL locus potentially explain-
ing previously reported GWAS results. Moreover, we report
meta-analysis results indicating that the rs13702 minor
allele associates with lower TAG (p ¼ 3.182 3 1042) and
higher HDL-C (p ¼ 1.316 3 1032) concentrations in
27,756 individuals fromCHARGE. In addition, our associa-
tion data suggest that greater intake of PUFA further
modulates this beneficial association with TAG. The 40%American Journal of Human Genetics 92, 5–14, January 10, 2013 9
Figure 2. The Minor C Allele of rs13702 Disrupts a Functional
miR-410 MRE in the hLPL 30 UTR
(A) Relative expression of miR-410 across various human tissue
samples. Expression is relative to lung.
(B) Expression of rs13702 T or C allele luciferase constructs in
COS-7 cells with miR-410 or control mimic (Cn-miR). Data are ex-
pressed as luciferase activity relative to control samples.
(C) Luciferase expression of rs13702 T allele construct with
increasing concentrations (5 nM, 10 nM, 20 nM, and 40 nM) of
miR-410 compared to control mimic.
All data represent experiments performed in triplicate. p values
were determined by the Student’s paired t test. *p < 0.01.
Table 3. Interaction Associations of LPL SNPs
SNP Phenotype Dietary Fat Beta SE p Value
rs13702 HDL-C MUFA 0.00070 0.00054 0.196
HDL-C PUFA 0.00132 0.00066 0.045
HDL-C SFA 0.00017 0.00060 0.778
LDL-C MUFA 0.00001 0.00006 0.863
LDL-C PUFA 0.00059 0.00069 0.397
LDL-C SFA 0.00025 0.00049 0.618
TAG MUFA 0.00174 0.00104 0.095
TAG PUFA 0.00778 0.00230 0.00153a
TAG SFA 0.00094 0.00106 0.375
rs2083637 HDL-C MUFA 0.00047 0.00126 0.706
HDL-C PUFA 0.00204 0.00195 0.294
HDL-C SFA 0.00011 0.00121 0.925
LDL-C MUFA 0.00101 0.00304 0.741
LDL-C PUFA 0.00219 0.00465 0.639
LDL-C SFA 0.00301 0.00292 0.304
TAG MUFA 0.00083 0.00159 0.600
TAG PUFA 0.00594 0.00236 0.012
TAG SFA 0.00022 0.00153 0.885
Results of interaction meta-analysis across ten cohorts for two LPL SNPs with
three dietary variables. Each cohort performed association analyses separately
for interactions. All studies utilized a linear regression analysis implementing an
additive genetic model while adjusting for age, gender, BMI, field center, and
population substructure variables. Meta-analysis of interactions was performed
with an inverse variance weighted analysis. n ¼ 27,756.
aanalyzed without GOLDN; p ¼ 0.00133.reduction in activity of a LPL luciferase reporter containing
the T allele cotransfected with a miR-410 mimic was abol-
ished when a LPL reporter containing the minor C allele
was used. These data indicate rs13702 as a likely causal
gain-of-function variant within the LPL locus.
The 30 UTR of mRNA transcripts is an essential mediator
of translational control.38 Within the 30 UTR are numerous
regulatory sequences which, in part, determine transla-
tional efficiency, mRNA localization, and stability.39 Trans-
lational repression is also mediated by miRs that inhibit or
degrade their target mRNA through complementary bind-
ing to 30 UTR MREs.17 Studies in model organisms have
determined that the LPL 30 UTR harbors various regulatory
sequences important for translational control that when
deleted increase relative abundance of LPL both in vitro
and in vivo.40,41 Hensley et al.40 demonstrated that mice
expressing an adipose-specific human LPL transgene void
of the 30 UTR sequence had lower levels of LPL mRNA but
an abundance of LPL protein relative to what would be
expected from mice expressing a transgene of the entire
human LPL mRNA. Although authors point to inhibitory10 The American Journal of Human Genetics 92, 5–14, January 10, 20mechanisms relating to catecholamine regulation and the
role of the poly(A) tail, another possibility is that the
human LPL 30 UTRharbors additional inhibitory sequences
related to the binding of miRs. Recently, a functional MRE
for miR-29a in the LPL 30 UTR was reported to mediate
inflammation in dendritic cells.42 Our data suggest that
another such sequence in human LPL is aMRE formiR-410.
The human miR-410 is one of more than 40 miRs clus-
tered at the conserved 14q32 locus.43 The miRs within
this cluster are most abundant in fetal and brain tissues,
although their expression has been demonstrated in
a variety of other tissue and cell types.26,43,44 Specifically,
expression of miR-410 has been demonstrated in adipose,
neuronal, endothelial, and other cell lines, but few targets
or functions have been revealed.27,42,45,46 Only one study
has demonstrated a role for miR-410, where its knockdown
in pancreatic MIN6 cells resulted in a decreased ability
to secrete insulin in response to glucose stimulation.
Furthermore, miR-410 overexpression in these same cells
enhanced the response of glucose-stimulated insulin secre-
tion.26 In the present study, we provide evidence of miR-
410 expression in adipose, heart, and skeletal muscle,
confirming the presence of miR-410 in the tissues with
high LPL expression.13
Figure 3. Population-Specific Effect of
the Interaction between rs13702 and
PUFA on TAG and HDL-C
Effect of interaction between rs13702 and
PUFA on (A) TAG and (B) HDL-C are
plotted. Here the Beta and SE represents
the difference in the magnitude of the
PUFA association (per unit intake of PUFA
expressed as a percentage of total daily
energy) with TAG (mmol/l) per copy of
the effect allele. Data are adjusted for
covariates age, sex, BMI, total energy, field
center, and population substructure vari-
ables. The overall effect frommeta-analysis
is also plotted.Our gene-by-diet interaction meta-analysis suggests that
increasing levels of dietary PUFAmay enhance the effect of
rs13702 on TAG concentrations (Table 3, Figure 3). LPL
harbors a PPRE in its promoter region, which evidence
suggests is responsive to both dietary and pharmacological
agents.31,32 We hypothesize that for subjects carrying at
least one copy of the rs13702 minor C, elevated dietary
PUFA intake will further increase LPL levels in the absence
of regulatory inhibition by miR-410. However, for those
individuals homozygous for the rs13702 major T allele,
any increase in LPL resulting from PUFA stimulation may
be subject to translational inhibition bymiR-410, resulting
in a less robust response to dietary PUFA (Figure 4). Hetero-
geneity was observed in the meta-analysis of interaction
for rs13702 and PUFA (Figure 3). The InCHIANTI and
YFS cohorts both showed nonsignificant interactions,
with their effects trending in the opposite direction from
the remaining eight cohorts. One possible explanation
for this discrepancy is that both InCHIANTI and YFS, rela-
tive to most other cohorts, had fewer total subjects and
lower intakes of PUFA as a percent of their total energy
(Table 1).
The observed statistical interaction between PUFA and
rs13702 may also indicate a regulatory response of miR-
410 to PUFA in vivo. Recently it was demonstrated that
miR-758, belonging to the 14q32 cluster, regulates the
ABCA1 mRNA in both mouse and human tissues. Further-
more, authors of this work demonstrated that miR-758
levels were downregulated in the macrophages and livers
of mice receiving a high-fat diet, suggesting a response of
miR-758 levels to dietary fat.44 Whether this regulation
occurs at the transcriptional or posttranscriptional level
is unclear. Currently, no conclusive data exist on whether
the miR genes within the 14q32 cluster are transcribed as
one large polycistronic noncoding RNA or individually
through independent promoters.43 At this time our inter-
action data are intriguing, but one must keep in mind
the limitations of using cross-sectional data for GxE inter-
action studies.47 Replication studies for the rs13702 and
PUFA interaction and laboratory experiments investi-
gating the effect of PUFA on miR-410 will be required to
clarify their combined role in the modulation of TAGThe Aconcentrations. Until this is done, no definitive conclusion
may be drawn regarding the interaction of rs13702 and
PUFA on TAG concentrations.
Our data suggest that the proposed mechanism of LPL
regulation by miR-410 is modulated by the common
rs13702 variant. Even though we show that the major T
allele induces regulation of LPL by miR-410, GenBank
and Haplotter both show that the ancestral allele for
rs13702 is the C allele.48 Moreover, the C allele is the
lower-frequency allele in the majority of human popula-
tions from HapMap.49 If the C allele is the predominant
nucleotide at the rs13702 position in our primate ances-
tors, we must consider that the T allele arose early in
humans and either drifted or was driven to relatively
high frequencies. At this time, we can only speculate on
the environmental conditions that may have influenced
the preference for the T allele at the rs13702 position.
One potential area of interest is suggested by the inhibition
of LPL activity during the immune acute phase response.50
A role for miR-410 in inflammation and acute phase
response remains to be determined.
Of relevance to this work is the report of numerous
recombination and mutation hotspots within LPL, sug-
gesting enhanced genotypic diversity at this locus among
human subjects.51 The relatively high rate of nucleotide
change within LPL is likely to account for the appearance
of rs13702, in addition to the many other rare and
common variants that have shown association with vari-
ability in lipid traits in human populations.12,52 LPL is
regulated through both overlapping and unique mecha-
nisms across different tissue types. SNPs that may interfere
with tissue-specific forms of regulation may explain why
LPL has been implicated in both pro- and antiatherogenic
processes.2 It may be the case that rs13702, and other SNPs
modulating LPL regulation and/or activity, have provided
a degree of phenotypic plasticity required for humans to
respond to varying environmental exposures.
In addition to rs13702, we provide association data for
rs2083637, a SNP shown to be in high LD with rs13702
across different populations. Indeed, significant results
from association analyses were similar between rs13702
and rs2083637 for main effects, but not for interactions.merican Journal of Human Genetics 92, 5–14, January 10, 2013 11
Figure 4. Allele-Specific Consequence of
rs13702 on the miR-410/LPL Interaction
Top: LPL levels are partially lowered by
miR-410 targeting of the LPL 30 UTR
induced by the rs13702 T allele. Dietary
PUFA may modulate miR-410 in addition
to LPL to further mediate this reduction
in LPL concentrations.
Bottom: LPL concentration is not affected
by miR-410 in the presence of the
rs13702 C allele, resulting in a relative
increase in LPL. The effect of dietary
PUFA on miR-410 will have no down-
stream effect on LPL concentration.
Solid arrows indicate interactions with
supporting in vitro evidence. Dotted
arrows indicate hypothesized interactions.Given the consistent effect of rs13702 and the supporting
functional data, we suggest that the intergenic rs2083637
is a marker for rs13702. Although we conclude that
rs13702 is the most likely functional candidate among
the other SNPs within its respective tagging block of LPL,
there is potential for a SNP(s) outside of this block to
explain the majority of the effect observed in our associa-
tion results. The second largest tagging block within LPL
contains rs328 (Table S1). rs328 and SNPs in LD with
rs328 have shown a gain-of-function association on TAG
and HDL-C in white populations, similar to rs13702. Inter-
estingly, a study investigating the effects of LPL variants on
TAG and HDL-C levels in a white population included
rs328 in the statistical model for the test of association
between rs13702 and TAG. The association was only
modestly affected by this adjustment and rs13702 re-
mained significantly associated with TAG and HDL-C
concentrations.9 These data suggest that rs13702 acts inde-
pendently of the SNPs in the rs328 LD block to affect lipid
levels. The authors of this work suggest rs13702 or a SNP in
LD with rs13702 as a functional variant.
Because of the excess of variability at the human LPL
locus, we cannot exclude the possibility that another
undiscovered variant in LD with rs13702 and rs2083637
or that acts in concert with rs13702 is responsible, in
part, for the significant associations observed here.53
However, we feel that our in vitro data in combination
with our statistical data provide strong support for the
functionality of the rs13702 SNP.
In summary, the data presented here suggest a role for
miR-410 in LPL regulation through an allele-specific
interaction with rs13702. Furthermore, our data support
rs13702 as the causal variant explaining SNPs previously
identified in GWAS as modulators of TAG and HDL-C
concentrations. Together with previous bioinformatic
analyses, we show how the collaborative efforts of bio-
informatics, epidemiology, and molecular biology can be
utilized for the identification and validation of functional
targets underlying GWAS results. Although further work is12 The American Journal of Human Genetics 92, 5–14, January 10, 20necessary to confirm in vivo regulation of LPL by miR-410,
there is potential for therapeutically targeting miR-410 in
hypertriglyceridemic subjects homozygous for the T allele.
Follow-up work on the proposed effect of the interaction
between rs13702 and dietary PUFA on TAG levels may
result in further therapeutic use for dietary regimens target-
ing lower TAG concentrations.Supplemental Data
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